Rita Nanda, MD

Dr. Nanda is an associate professor of medicine and co-director of the breast medical oncology program at The University of Chicago. Her research interests include identifying new treatments for breast cancer, with a focus on triple-negative disease. She leads the University of Chicago’s clinical and translational breast cancer research efforts, and serves as a principal investigator for the Translational Breast Cancer Research Consortium (TBCRC) and the ISPY2 Clinical Trial Network. She is a member of several professional organizations, including the American Society of Clinical Oncology, the American Association of Cancer Research, and the Society for Immunotherapy of Cancer.

Dr. Nanda has authored many scientific publications and book chapters, including one of the first reports of immune checkpoint inhibitor therapy for triple-negative breast cancer. She presents her research often at national and international conferences. She has earned several awards, including the 2014 NCI Cancer Clinical Investigator Team Leadership Award.

Contributions